Business Wire

ANT-GROUP/KOMINFO

24.5.2022 07:33:06 CEST | Business Wire | Press release

Share
Kominfo Partners with 10x1000 Tech for Inclusion to Bring “Flex” Fintech Foundation Program to Indonesia

The Ministry of Communication and Informatics (“Kominfo”) today announced its partnership with fintech training platform 10x1000 Tech for Inclusion (“10x1000”) to recruit local talents to enroll in 10x1000’s “Flex” Fintech Foundation Program.

This partnership forms part of Kominfo’s Digital Entrepreneurship Academy (“DEA”) program, which aims to prepare and nurture talents to accelerate digital transformation in the field of entrepreneurship and to improve the digital economy, with a target of 60,000 people being trained in 2022.

“The Ministry of Communication and Informatics appreciates the collaboration with 10x1000 to carry out digital entrepreneurship training through the DEA program. The results of the program are expected to improve the quality of Micro, Small and Medium Enterprises (MSMEs) and promote the digital economy in Indonesia,” said Hary Budiarto, Head of HR & Research Agency, Ministry of Communication and Informatics (Kominfo).

With the vision to train 1,000 emerging talents and tech leaders each year for ten years, 10x1000 saw a total of 1,067 learners from 66 countries and regions complete its “Flex” Fintech Foundation Program and Fintech Leadership Program in 2021. Of which, more than 150 learners were from Indonesia, making the country the second largest globally in terms of learner intake.

“We are deeply encouraged by the overwhelming responses from Indonesia last year, and excited to partner with Kominfo to further expand the reach in Indonesia and make 'Flex' available to more local entrepreneurs and professionals to enhance their fintech mindset, knowledge and skills to better allow them to drive digital economic growth,” said Mr. Jason Pau, Program Lead of 10x1000. “Technology pervades nearly every aspect of our lives, and we hope this partnership will help Indonesia bridge its digital skills gap while empowering and improving the lives of local communities. Together with Kominfo and other local partners, we look forward to contributing more to Indonesia’s digital development goals.”

“The Coordinating Ministry of Human Development and Culture also expresses our appreciation to Kominfo for taking the initiative in driving such fintech training collaborations for women entrepreneurs and MSMEs (an initiative of the Ministry) with 10x1000,” said Femmy Eka Kartika Putri, Deputy of Coordination for Quality Improvement of Children, Women and Youth, Coordinating Ministry for Human Development and Culture (Kemenko PMK). “At least 60% of MSMEs in Indonesia are managed by women and contribute at least 61.07% of the country's GDP. With the 'Flex' Fintech Foundation Program by 10x1000 Tech for Inclusion, it will encourage women entrepreneurs to further enhance their businesses through digital technology. The training program is expected to help women entrepreneurs and MSMEs overcome challenges such as limited access to entrepreneurship and understanding of digital technology, as well as difficulties in obtaining access to capital.”

Registration for the “Flex” Fintech Foundation Program is now open through Kominfo’s Digital Entrepreneurship Academy website here . The first batch of training is slated to start on 6 June. Local fintech and banking associations will support the initiative by inviting their members to enroll the program as well, including the Indonesia Fintech Association (AFTECH), Indonesian Joint Funding Fintech Association (AFPI), Indonesian Sharia Fintech Association (AFSI), Indonesian Crowdfunding Service Association (ALUDI), Indonesian Blockchain Association (ABI), Association of Indonesia Shariah Banks (ASBISINDO), Indonesian Sharia Insurance Association (AASI), Association of National Commercial Banks (PERBANAS), and Indonesian E-commerce Association (idEA).

The partnership with Kominfo is the latest effort by 10x1000 to deepen its collaborations with partners worldwide. Globally, 10x1000 has forged partnerships with the IFC, United Nations Economic Commission for Africa, UN World Food Programme, SME Finance Forum Managed by the IFC, Dubai International Financial Centre, MDEC, KPMG and fintech associations from Hong Kong, Singapore, Malaysia, MENA, the Philippines and Thailand to recruit learners and grow the community.

About KOMINFO
Ministry of Communication and Informatics is responsible to carrying out government affairs in the field of communication and information technology to assist the President in administering government. Its main task and function to formulate national policies, implementation policies, and technical policies in the field of communication and informatics which include post, telecommunications, broadcasting, information and communication technology, multimedia services and information dissemination. The Ministry of Communications and Informatics is led by a Minister of Communication and Information (Menkominfo) who since October 23, 2019 has been held by Johnny Gerard Plate.

About DEA
The Digital Entrepreneurship Academy (DEA) is a program from the Ministry of Communication and Information that aims to prepare digital talent to accelerate Indonesia digital transformation in the field of digital entrepreneurship in order to improve the digital economy, with a target of 60,000 people being trained in 2022. The targets of this program include creating new digital entrepreneurs, upskilling advanced digital entrepreneurs, and developing digital entrepreneurship in inclusive villages. More details of the program please visit https://komin.fo/DEA .

About 10x1000 Tech for Inclusion
10x1000 Tech for Inclusion is an open and global fintech training platform that enables learners to become drivers of digital economic growth. Its mission is to train 1,000 emerging talents and tech leaders each year for the next ten years. 10x1000 is a philanthropic initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye